TLN1 and prostate carcinoma: The drug-induced MET was prevented by talin1 overexpression in DU-145 androgen-independent prostate cancer cells, in accord with recent evidence suggesting that talin1 loss impaired EMT and consequential acquisition of cell motility [28].